The spokesperson said that the program, called the Collaboration on Gene Therapies Global Pilot, is part of the agency’s work toward global regulatory harmonization of these products. The FDA is working with international partners, global regulators and the World Health Organization on these efforts, they said.
While it’s still early on in development, the pilot will explore the possibility for “concurrent collaborative” review of applications alongside global regulatory partners.
“While countries around the world have their own regulatory authorities, there are no uniform global standards for the evaluation and regulation of cell and gene therapy products,” the spokesperson said. “We believe that harmonization efforts in this area can help facilitate more efficient clinical development.”
The FDA has also used this approach for Project Orbis, which it established in 2019 to provide a pathway for concurrent submission and review of oncology products.
The pilot for gene therapy products comes as the agency has tightened its focus on gene therapies and rare disease in recent years.
This past fall, the FDA launched an Operation Warp Speed-like pilot program for rare disease to speed the approval process. FDA’s Peter Marks has also previously said that the agency is pushing the accelerated approval pathway for rare disease products.
https://endpts.com/fda-develops-pilot-to-harmonize-international-gene-therapy-regulations/
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
MeiraGTx’s AAV Gene Therapy Shows Promising Results for Parkinson’s
MeiraGTx has reported encouraging results from a midphase trial of its investigational gene therapy, AAV-GAD, for treating Parkinson’s disease. The company is now in discussions with regulators to advance the program to Phase III clinical trials.Significant...
[2024/10/11] Gene and Cell Therapy- weekly digest from PackGene
FeaturedNewsArticlesPackGene's NewsletterReceive the latest news and insights to your inbox.About PackGenePackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span...
Ultragenyx Provides Update on Stage 1 Cohorts in Phase 1/2/3 Cyprus2+ Study for Wilson Disease with AAV9 Gene Therapy
October 3, 2024 NOVATO, Calif. — Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) has announced promising results from the ongoing Phase 1/2/3 Cyprus2+ study evaluating UX701 gene therapy for Wilson disease. Early-stage data from Stage 1 of the trial revealed significant...
World-First CAR-T Therapy Using Donor Cells Sends Autoimmune Diseases into Remission
In a groundbreaking advancement, three individuals suffering from severe autoimmune diseases have achieved remission after receiving a revolutionary therapy using donor-derived immune cells. This pioneering treatment, which utilized bioengineered immune cells known as...
Related Services